Ultragenyx Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on November 14, 2018. The filing reports a material event regarding the company's drug development pipeline rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event and does not contain financial statement data.
Material Changes
The primary material event reported is the company's announcement of its intent to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its candidate drug, UX007. The submission is targeted for mid-2019. The drug is intended for the treatment of long-chain fatty acid oxidation disorders.
Outlook and Management Commentary
Management's outlook is centered on the anticipated regulatory milestone for UX007. The company expects to submit the NDA in mid-2019. No specific financial guidance, risk factors, or contingencies beyond the standard regulatory approval process are detailed in this specific filing text.
Investor Verification Checklist
- Verify the exact timeline for the UX007 NDA submission in mid-2019.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical data supporting the application.
- Monitor subsequent FDA communications regarding the acceptance of the NDA.
- Check the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.